Rivipansel: In August 2019, Pfizer reported disappointing results from the Phase 3 RESET trial (NCT02187003) after it failed to meet the primary endpoint of the study. A post hoc analysis of the Phase 3 RESET study evaluating the efficacy of rivipansel in acute vaso-occlusive crisis (VOC) showed that patients treated with rivipansel early in their crisis experienced statistically significant improvements in the primary efficacy endpoint of time to readiness for discharge compared to placebo. In addition, biomarker data showed reductions in soluble E-selectin confirming that rivipansel hit its intended biological target. GycoMimetics believes that these findings confirm the critical role of E-selectin in acute vaso-occlusion, as well as the importance of treating individuals early in the course of their acute painful crisis. These data are contained in abstracts published online (see page 26) in June 2020 and were presented at the September 23-25 meeting of the Foundation for Sickle Cell Disease Research (FSCDR) and in greater detail at the ASCAT meeting in late October 2020.
GlycoMimetics has discontinued development of rivipansel for the treatment of vaso-occlusive crisis in sickle cell disease as of early 2021, and instead, is preparing to initiate clinical development on a more potent molecule, GMI-1687, for potential subcutaneous administration in the outpatient setting.